Truncated recombinant AAV genomes can compromise transgene expression and the therapeutic efficacy1 of gene therapy vectors, making genome integrity a critical quality attribute, highlighting the need for robust analytical methods.
Long‑read sequencing platforms, such as Oxford Nanopore Technologies (ONT), enable direct, full‑length rAAV genome analysis and offer a powerful approach for genome integrity assessment2,3. Establishing key performance characteristics, like repeatability (intra‑assay precision) and intermediate precision, becomes essential for use in quality control and release‑testing.
This study assessed the repeatability and intermediate precision of a long‑read sequencing-based genome integrity assay using replicate control DNA and self‑complementary AAV (scAAV) samples across independent preparations.
Get the full details in our whitepaper: Repeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencing
